The Karma research group at Karolinska Institutet is creating the world’s best-characterised breast cancer cohort. The aim is to reduce the mortality and incidence in breast cancer through translational research focusing on breast cancer screening and prevention.

READ MORE ABOUT THE KARMA STUDY

The Karma research group at Karolinska Institutet is creating the world’s best-characterised breast cancer cohort. The aim is to reduce the mortality and incidence in breast cancer through translational research focusing on breast cancer screening and prevention.

READ MORE ABOUT THE KARMA STUDY

Recent news

2020-10-28

Karma starts new clinical trial on contrast enhanced mammography

Enrolment to Karma Kontrast is now starting. Karma Kontrast is a randomised clinical trial conducted at the mammography unit at Södersjukhuset (Stockholm South General Hospital), Sweden, in collaboration with researchers at Karolinska institutet. The trial will study if contrast enhanced mammography can be used to improve mammography screening. Karma Kontrast is anticipated to go on...
2020-01-31

Karisma 2 Biopsy study on low-dose tamoxifen

Analyses are ongoing in the Karisma 2 Biopsy study. Karisma 2 Biopsy is a nested cohort within the Karisma 2 clinical trial on low-dose tamoxifen, conducted during 2017-2019 in Sweden. In all, 96 participants donated breast biopsied before and after treatment with tamoxifen or placebo. Analyses are ongoing and results are expected after the summer. 
2019-11-10

Karisma 2 clinical trial on low-dose tamoxifen is completed

We have now completed the Karisma 2 randomised clinical trial on low-dose tamoxifen. In all, 1,440 women were included in the Swedish two-centre study, at Södersjukhuset in Stockholm and at Unilabs in Lund.  The results are being analysed and the first paper is expected to be published after the summer 2020.  Karisma-2 is a dose optimisation...
More news
LOG IN

Log in to the Karma Research Platform here

Not a member? REGISTER HERE...
Interview

Professor Per Hall talks about Karma